TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole
Category: #health  By Mateen Dalal  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole

TFF Pharmaceuticals, Inc., claims that it has initiated Voriconazole Inhalation Powder’s phase 1 clinical trial —Voriconazole’s inhaled dry powder version that is direct-to-lung and complements next-generation version. When it comes to the treatment of Invasive Pulmonary Aspergillosis (IPA), Voriconazole Inhalation Powder is regarded as the most efficacious antifungal drug.

Reportedly, the trial will start patients’ dosing this week and is slated to be undertaken at a site in Canada meant for assessing pharmacokinetic profile, tolerability and safety of Voriconazole Inhalation Powder in over 64 health subjects. The trial is anticipated to be evaluated under a Canadian CTA and US IND.

TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology platform leverages liquid Voriconazole’s reformulation into dry powder particles with attributes perceived to be apt for inhalation delivery. For the uninitiated, the Voriconazole dry powder formulation aims at the fungal infection site in the lung and has the innate capability to be the first dry powder inhaled fungicide in the industry.

President and CEO of TFF Pharmaceuticals Glenn Mattes was all praise for TFF Pharmaceuticals that has taken a giant leap from research to product formulation to clinical trial study for Voriconazole Inhalation Powder. Mattes believes this a massive stride taken by the company and TFF technology has lived up to the expectations of innovation and viability. He went to state that TFF Pharmaceuticals will leave no stone unturned in developing new drugs with a range of commercial applications for lung condition and chronic respiratory diseases.

University of Texas Health Science Center’s Professor and Chief of Pulmonary and Critical Care, Jay Peters commented that the development of Voriconazole Inhalation Powder for the treatment of IPA is underpinned by the preclinical data produced from early animal testing with the TFF technology platform. He further asserted that the start of the first human dosing was a quantum leap towards developing an essential new drug for critically ill patients who are inflicted from IPA. Inhaled Voriconazole is believed to be instrumental in treating allergic bronchpulmonary aspergillosis (ABPA).
 

Source Credits: https://ir.tffpharma.com/news-releases/news-release-details/tff-pharmaceuticals-announces-initiation-phase-1-clinical-trial

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Meter nabs $38Mn to scale business & support faster enterprise internet
Meter nabs $38Mn to scale business & support faster enterprise internet
By Mateen Dalal

Meter, Inc., an internet & Wi-Fi infrastructure provider for businesses, has recently announced that it has successfully raised $38 million in a Series B funding round that was headed by Lachy Groom and Sequoia Capital. Industry leaders like D...

MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
By Mateen Dalal

The BNPL (book now pay later) payment has been introduced on MakeMyTrip on bookings for flights, travel, or hotels as well as on the Goibibo app MakeMyTrip, the online travel company, has recently said that it has collaborated with 15 banks, finte...

BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
By Mateen Dalal

BlackBerry Limited, a Canada-based software company focused on cybersecurity, has recently entered into a partnership with Midis Group, a leading technology company offering advanced hardware and software solutions, to expand its market footprint acr...